公开(公告)号：US12128010B2

公开(公告)日：2024-10-29

申请号：US17833836

申请日：2022-06-06

Applicant: NOVALIQ GMBH

Inventor： Dieter Scherer ,  Ralf Grillenberger ,  Frank Löscher ,  Hartmut Voss

IPC: A61K31/02 ,  A61F9/00 ,  A61K9/00 ,  A61K9/08 ,  A61P27/02

CPC classification number: A61K31/02 ,  A61F9/0008 ,  A61K9/0048 ,  A61K9/08 ,  A61P27/02

Abstract: The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

公开(公告)号：US20240350593A1

公开(公告)日：2024-10-24

申请号：US18621336

申请日：2024-03-29

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  SORBONNE UNIVERSITE ,  UNIVERSITÉ PARIS CITÉ ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Inventor： Francine BEHAR-COHEN ,  Raphael COHEN ,  Rinath LEVY-BOUKRIS ,  Min ZHAO

IPC: A61K38/38 ,  A61K38/01 ,  A61K47/36 ,  A61P27/02 ,  A61K31/573

CPC classification number: A61K38/38 ,  A61K38/014 ,  A61K47/36 ,  A61P27/02 ,  A61K31/573

Abstract: This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.

公开(公告)号：US20240350402A1

公开(公告)日：2024-10-24

申请号：US18687993

申请日：2022-08-30

Applicant: The Cleveland Clinic Foundation

Inventor： Steven E. WILSON

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/4178 ,  A61K31/573 ,  A61P27/02

CPC classification number: A61K9/0048 ,  A61K9/0051 ,  A61K9/06 ,  A61K31/4178 ,  A61K31/573 ,  A61P27/02

Abstract: The present invention relates to compositions, systems, and methods for treating a subject with a corneal injury and/or an existing corneal scar using a composition comprising an ACE-2 receptor antagonist (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the ACE-2 receptor antagonist is present in the composition at a concentration of about 0.2 mg/ml to 0.9 mg/ml or about 0.1 mg/ml to 2.0 mg/ml.

公开(公告)号：US12121585B2

公开(公告)日：2024-10-22

申请号：US18101636

申请日：2023-01-26

Applicant: Ashvattha Therapeutics, Inc.

Inventor： Jeffrey L. Cleland ,  Rishi Sharma ,  Santiago Appiani

IPC: A61K47/59 ,  A61K31/404 ,  A61K49/00 ,  A61P27/02 ,  C08G73/02

CPC classification number: A61K47/595 ,  A61K31/404 ,  A61K49/0034 ,  A61K49/0054 ,  A61P27/02 ,  C08G73/028

Abstract: Dendrimer compositions and methods for the treatment of one or more inflammatory and/or angiogenic diseases and/or disorders of the eye include hydroxyl-terminated dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of the diseases of the eye, and/or for diagnosing the diseases and/or disorders of the eye. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be VEGFR tyrosine kinase inhibitors including sunitinib or analogues thereof. Preferably, the compositions are suitable for administration via a systemic route to target activated microglia/macrophages in retina/choroid.

公开(公告)号：US20240343814A1

公开(公告)日：2024-10-17

申请号：US18760575

申请日：2024-07-01

Applicant: Viridian Therapeutics, Inc.

Inventor： Vahe BEDIAN ,  Yang ZHAO

IPC: C07K16/28 ,  A61K31/7088 ,  A61K35/12 ,  A61P27/02 ,  C07K16/46

CPC classification number: C07K16/2863 ,  A61K31/7088 ,  A61K35/12 ,  A61P27/02 ,  C07K16/461 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/94

Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.

公开(公告)号：US12109302B2

公开(公告)日：2024-10-08

申请号：US18227463

申请日：2023-07-28

Applicant: Ocular Therapeutix, Inc.

Inventor： Charles D. Blizzard ,  Rami El-Hayek ,  Michael Goldstein ,  Peter Jarrett ,  Andrew Vanslette

IPC: A61K9/00 ,  A61K38/13 ,  A61K47/10 ,  A61K47/22 ,  A61P27/02

CPC classification number: A61K9/0051 ,  A61K38/13 ,  A61K47/10 ,  A61K47/22 ,  A61P27/02

Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

公开(公告)号：US20240316219A1

公开(公告)日：2024-09-26

申请号：US18558919

申请日：2022-05-02

Applicant: NORTH CAROLINA STATE UNIVERSITY ,  THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Inventor： Brian Gilger ,  Elizabeth Crabtree ,  Matthew L. Hirsch

IPC: A61K48/00 ,  A61K9/00 ,  A61P27/02 ,  C07K14/54 ,  C12N15/86

CPC classification number: A61K48/005 ,  A61K9/0048 ,  A61K48/0075 ,  A61P27/02 ,  C07K14/5428 ,  C12N15/86 ,  C12N2750/14143

Abstract: The present disclosure provides compositions and methods related to the treatment of ocular diseases in equines. In particular, the present disclosure provides novel compositions and methods related to the administration of therapeutic compositions comprising AAV-equine IL-10 for the treatment and/or prevention of various ocular diseases (e.g., non-infectious uveitis).

公开(公告)号：US20240316053A1

公开(公告)日：2024-09-26

申请号：US18574162

申请日：2022-06-23

Applicant: LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD.

Inventor： Yongzhi CHENG ,  Rui GU ,  Zenglin LIAN

IPC: A61K31/519 ,  A61K31/198 ,  A61P27/02

CPC classification number: A61K31/519 ,  A61K31/198 ,  A61P27/02

Abstract: A drug for treating dry eye, a method for improving wearing experience in populations with contact lens discomfort, and eye drops for treatment.

公开(公告)号：US20240315301A1

公开(公告)日：2024-09-26

申请号：US18699259

申请日：2021-10-05

Applicant: ALGAE HEALTH SCIENCES CO., LTD.

Inventor： Takahiro SEKIKAWA ,  Yanmei LI

IPC: A23L33/15 ,  A61K31/355 ,  A61P27/02

CPC classification number: A23L33/15 ,  A61K31/355 ,  A61P27/02

Abstract: A composition for improving vision selected from more than one of uncorrected vision, corrected vision, and practical vision, containing a component (A) or the component (A) and a component (B). The component (A) is selected from at least one of Astaxanthin (ASX) or an ester of the Astaxanthin; and the component (B) is Vitamin E (VE).

公开(公告)号：US12097209B2

公开(公告)日：2024-09-24

申请号：US17624311

申请日：2020-06-30

Applicant: Oculis Operations Sàrl

Inventor： Thorsteinn Loftsson ,  Zoltán Fülöp

IPC: A61K31/573 ,  A61K9/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/40 ,  A61P27/02 ,  A61P29/00

CPC classification number: A61K31/573 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/40 ,  A61P27/02 ,  A61P29/00

Abstract: A method is described of stabilizing the pH of an aqueous composition including a drug that is prone to oxidation. The method includes adding an additive to prevent oxidation of the drug that is prone to oxidation. Also described, is a method of stabilizing the pH of an aqueous composition including a corticosteroid, the method including adding an additive to prevent oxidation of the corticosteroid. Further, a composition is described that includes a corticosteroid and an additive to prevent oxidation of the corticosteroid.